Nanoviricides, Inc.
NNVC NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.36
KIRA · Stoqly’s AI analyst, in plain words
- Nanoviricides, Inc. had $0.0M of revenue in fiscal 2026.
- Nanoviricides, Inc. lost $8.2M in fiscal 2026.
- Free cash flow was −$7.8M in fiscal 2026, — of revenue.
Market cap
$27.5M
P/E
—
Revenue
$0.0M
Net income
−$8.2M
Free cash flow
−$7.8M
Operating margin
—
Nanoviricides, Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$8.2M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nanoviricides, Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 28, 2026
- Legal name
- NANOVIRICIDES, INC.
- CIK
- 0001379006
Nanoviricides, Inc. · NNVC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$8.1M | −$8.6M | −$8.3M | −$9.5M | −$8.2M |
| Diluted EPS | −$0.70 | −$0.74 | −$0.70 | −$0.63 | −$0.41 |
| Cash | |||||
| Cash from operations | −$5.9M | −$5.7M | −$6.3M | −$8.5M | −$7.7M |
| Capital expenditure | $0.3M | $0.2M | $0.2M | $0.1M | $0.1M |
| Free cash flow | −$6.2M | −$5.8M | −$6.5M | −$8.5M | −$7.8M |
| Share count change | 5.8% | 0.8% | 2.1% | 27.3% | 33.5% |
| Debt and strength | |||||
| Cash and short-term investments | $14.1M | $8.1M | $4.8M | $1.6M | $2.8M |
| Shareholders' equity | $23.1M | $14.9M | $11.5M | $7.5M | $8.7M |
| Current ratio | 34.9x | 15.8x | 3.7x | 1.3x | 2.7x |
| Interest coverage | −1,590.9x | −9,937.2x | −171.0x | −95,916.0x | — |
| Returns and quality | |||||
| Return on equity | −30.6% | −45.3% | −63.0% | −99.7% | −101.5% |
| Return on tangible equity | −35.7% | −59.1% | −74.5% | −131.5% | −98.1% |
| Piotroski F-score | — | — | 1 | 1 | 3 |
| Altman Z'' | 43.3 | −18.1 | −29.2 | −56.0 | −48.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nanoviricides, Inc. · NNVC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.36 a share, the company is worth $27.5M.
Source: SEC EDGAR XBRL filings (CIK 0001379006). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.